MPA Meningioma Risk: Key Insights and Implications

By Crystal Lubbe

January 22, 2025

The South African Health Products Regulatory Authority (SAHPRA) has issued a clarification regarding the benefits and risks associated with medroxyprogesterone acetate (MPA), a synthetic form of the hormone progesterone. This substance is used for contraception, managing endometriosis-associated pain, and treating certain cancers. SAHPRA has updated the safety warnings for MPA-containing products to include the potential MPA meningioma risk based on epidemiological studies conducted in France and the United States.

Key Insights

SAHPRA identified an increased risk of meningioma associated with prolonged use of MPA. Although the absolute risk remains low, only 32 cases have been reported globally over the past 20 years. MPA appears in various products, such as Depo-Provera, Provera, Petogen, Medroxyprogesterone Mylan, Sayana, Omrastoz, Trivina, and Triclogyn. Healthcare professionals commonly prescribe these products for contraception, managing endometriosis, and providing palliative care for certain cancers. Providers should monitor patients for signs of meningioma and stop MPA use if diagnosed, particularly when used for non-oncological reasons. Patients should discuss potential side effects with their healthcare providers. SAHPRA also urges the public and healthcare professionals to report any suspected adverse drug reactions related to MPA.

Background Context

This update stems from regulatory actions in Europe, prompted by studies identifying an increased risk of meningioma with prolonged MPA use. Similar risks were observed with other progestogens, such as medrogestone and promegestone, though these are not currently marketed in South Africa. Meningiomas are typically benign tumors that develop from the membranes surrounding the brain and spinal cord. They are more common in women and tend to occur in middle-aged and older adults.

Implications

The updated safety warnings on MPA products may change how patients and providers assess risks and benefits. While MPA’s benefit-risk profile is still favorable, the added meningioma risk could, therefore, affect treatment decisions. This may lead to higher monitoring costs and revised treatment plans. Moreover, healthcare systems may need more resources to monitor and manage potential meningioma cases. As a result, this could strain budgets and impact resource allocation. Additionally, patient compliance might decline if concerns about side effects grow. Consequently, clear education and counseling will be vital to keep patients on treatment.

Furthermore, enhanced reporting of adverse reactions is essential to track meningioma cases linked to MPA. Stronger pharmacovigilance practices will, in turn, improve safety and management. Overall, SAHPRA’s update reinforces the need for active monitoring and safety measures. These efforts ensure safer treatments and better health outcomes.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.